Ipsos Rolls Out Hematology Monitor

Ipsos Healthcare has launched a new syndicated Molecular Diagnostics (MDx) Monitor, focusing specifically on hematological malignancies.

The MDx Monitor has been running in the USA since 2012, launched in the EU in 2013, and was rolled out in Japan and Australia last year. The new Hematological Malignancies MDx Monitor measures and tracks the usage of companion diagnostics (CDx) and other tests across a range of leukemias and lymphomas, covering the US now and the EU5 and other markets shortly. Based on the same overall approach that has been applied to the solid tumors Oncology MDx Monitor, the new MDx has been modified to account for the different testing paradigms in liquid tumors.

A panel of hematologists, medical oncologists and hematological oncologists, alongside a separate panel of (hemato-)pathologists complete a perceptual questionnaire as well as a number of actual, de-identified patient record forms and tissue/sample forms. The study captures both perceptual and behavioral data on cytogenetics, mutational analysis, flow cytometry, minimal residual disease monitoring and other molecular markers. Initially, it focuses on CML, CLL, AML and NHL (indolent and aggressive), with additional cancer types to be added in subsequent waves.

Pieter De Richter, Head of Ipsos Healthcare's Molecular Diagnostics Portfolio, comments: 'The molecular diagnostics market in the leukemia/lymphoma space is currently undergoing something of a revolution. With the launch of this new study, we now offer the most comprehensive coverage of MDx/CDx testing in the oncology space, covering a large number of tests and methodologies across a wide range of tumor types'.

Web site: www.ipsos.com .